Full Disclosure Policy Affecting CME Activities:
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Speakers are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:
| SPEAKERS NAME AND LECTURE TITLE(S) | RELATIONSHIP(S) |
| Clifton Bingham, III, MD
Rheumatoid Arthritis
|
Consultant/Advisor: Abbott, Amgen, Bristol-Myers Squibb, Celgene, Centocor/Johnson & Johnson/Janssen, Genentech/Roche, Millenium, Pfizer, UCB
Grants/Research Funding: Abbott, Amgen, Bristol-Myers Squibb, Celgene, Centocor/Johnson & Johnson/Janssen, Genentech/Roche, Pfizer, UCB Patent Royalty/Intellectual property rights: Up-to-Date
|
| Lisa Christopher-Stine
What’s New in Myositis |
Patent Royalty/Intellectual property rights: INOVA Diagnostics |
| Megan Clowse
Pregnancy and Rheumatology
|
Consultant/Advisor: UCB
|
| Grant Louie
The Spondyloarthropathies: Updates on Diagnoses and Treatments
|
Consultant/Advisor: UCB |
| Michelle Petri | |
| New Guidelines for Diagnosis and
Treatment of Lupus
|
Consultant/Advisor: GlaxoSmithKline; HGS; Medimmune; Pfizer; UCB |
| Deborah Sellmeyer
Osteoporosis: An Update
|
Grant/Research Funding: Amgen, Inc.; Eli Lilly, Inc. |
| Philip Seo | |
| Vasculitis
|
Consultant/Advisor: Genentech |
| Robert Terkeltaub | |
| Gout: Understanding New Treatments | Consultant/Advisor: ARDEA; BioCryst; Metabolex; Novartis; Pfizer; Regeneron; Savient; Takeda |
No other speakers have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).
| PLANNERS | |
| NAME | RELATIONSHIP(S) |
| Clifton Bingham | |
| Consultant: Allos; Celgene; Centocor; Flexion; Genentech/Roche; Millenium; Pfizer; UCB |
No other planners have indicated that they have any financial interests or relationships with a commercial entity.
Note: Grants to investigators at the Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:
| NAME AND LECTURE TITLE(S) | PRODUCT |
| Clifton Bingham, III, MD
Rheumatoid Arthritis
|
Drugs in mid-late phase clinical development for RA including Tofacitinib, Fostamatinib and others
|
| Francesco Boin | |
| Scleroderma: Early Diagnosis and
Management
|
Amplodipine; Cyclophosphamide; Epeprostenol; Mofetil Mycophenolate; Prednisone; Sildenafil |
| Lisa Christopher-Stine | |
| What’s New in Myositis | Essentially every medication used for the treatment of the idiopathic inflammatory myaopthies is used off-label (including Azathioprine, Methotrexate, Mycophenolate and Rituximab)
|
| Megan Clowse | |
| Pregnancy and Rheumatology | No rheumatologic medications have been approved specifically for use in pregnant patients. The FDA pregnancy classification for each medication will be reported. |
| Laura Hummers | |
| Difficult Cases in Scleroderma | Boesentan; Cyclophosphamide; Dasatinib; Epoprostenol; Imatinib; IVIG; Macentanten; Mofetil; Mycophenolate; Sildenafil; Tadalafil; Tocilizumab; Treprostenil
|
| Stuart Levine | |
| Clinical Vignettes with Audience
Response
|
Bisphosphonate therapy for complex regional pain syndrome |
| Grant Louie | |
| The Spondyloarthropathies: Updates
on Diagnoses and Treatments
|
Abatacept; Apremilast; Rituximab |
| David Moller | |
| Sarcoidosis: Advances in the
Diagnosis and Treatment
|
Adalimumab; Azathioprine; Corticosteriods; Etanercept; Golimumab; Infliximab; Leflunamide; Methotraxate; Mycophenylate; |
| Michelle Petri | |
| New Guidelines for Diagnosis and
Treatment of Lupus
|
Abatacept; Leflunomide; Mycophenolate; Tacrolimus; |
| Philip Seo | |
| Vasculitis | There are essentially no drugs that are FDA-approved for the treatment of vasculitis, with the exception of Rituximab for granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis |
| Robert Terkeltaub | |
| Gout: Understanding New
Treatments |
Anakinra; Canakinumab; Rilonacept; BCX4208 for gout |
No other speakers have indicated that they will reference unlabeled/unapproved uses of drugs or products
In Internet CME, discussions of unlabeled/unapproved uses can be color coded to alert the reader to this fact, and in other enduring materials, alert the audience to impending discussions in the text (use asterisk *) or verbally if video or audio format.
